KITE University Health Network
Toronto, Ontario, M5G 2A2, Canada
NCT Number: NCT07709936
After concussion, many individuals experience vision-related symptoms such as blurred vision, difficulty reading, and discomfort in visually stimulating environments, which can interfere with return to work, school, and daily activities. Oculomotor rehabilitation (OMR) is used by some clinicians to address these symptoms, but there is limited high-quality evidence to support its use. Prior to conducting a fully powered randomized controlled trial, it is necessary to determine whether such a study is feasible. This study aims to evaluate the feasibility of conducting a randomized trial comparing a six-week OMR program to usual care in adults with concussion. Adults aged 18 to 42 years who sustained a concussion 30 days to 12 months prior and report symptoms suggestive of oculomotor impairment will be recruited from an outpatient concussion clinic at the University Health Network and the community in Toronto, Ontario. Participants will be randomized to either a six-week OMR program consisting of weekly 60-minute clinic visits using head-mounted eye-tracking technology with prescribed home exercises, or usual care consisting of education and symptom management strategies. Feasibility outcomes will include recruitment rate, retention, perceived benefit of the OMR intervention, and safety (adverse events). Outcomes will be assessed at baseline and after six weeks. The findings will inform the design and implementation of a future trial evaluating the effectiveness of oculomotor rehabilitation after concussion.
Looking for future studies?
Notify Me18 year–42 year
All sexes
Interventional
Not applicable
Toronto, Ontario, M5G 2A2, Canada
Background Concussion is a common form of mild traumatic brain injury (mTBI) that produces a broad and heterogeneous range of symptoms and functional deficits affecting daily activities including work, school, sport, and social participation. Recovery is highly individualized and influenced by injury characteristics, personal medical history (e.g., anxiety, migraine history), and biological sex and sociocultural gender. Over 50% of individuals from the general population experience symptoms beyond four weeks. In mixed-mechanism populations, mean time to recovery is approximately 6.5 weeks for females and 5.5 weeks for males, suggesting that females may experience a longer symptom course following concussion.
Among the most prevalent clinical profiles of concussion are symptoms attributable to oculomotor dysfunction. Functional deficits in saccades, smooth pursuits, vergence, and pupillary light reflex occur far more frequently than structural injuries, making them a feasible and clinically important rehabilitation target. These deficits can manifest as blurred vision, dizziness, light sensitivity, eye strain, and difficulty tolerating visually busy environments, with downstream impacts on return to work, school, and sport. Without directed rehabilitation, these symptoms often persist.
Oculomotor rehabilitation (OMR) aims to retrain impaired eye movement functions through targeted, restitutive exercise protocols. A systematic review conducted by the study team demonstrated improvements in near point of convergence, reading rate, and visual search and attention following OMR; however, certainty of evidence was rated as low due to methodological limitations, small sample sizes, and variability in protocols. Since that review, additional studies have been published strengthening the evidence base, though existing randomized controlled trials have focused predominantly on adolescents and young adults, limiting generalizability to older adult populations.
Interest in virtual reality (VR)-based OMR delivery has grown substantially. A recent scoping review identified 10 studies using VR for post-concussion vestibular rehabilitation, reporting good tolerability and greater participant enjoyment relative to traditional approaches. To the investigators' knowledge, no published study has systematically examined the feasibility, acceptability, or perceived benefit of delivering OMR via head-mounted VR goggles combined with mobile application-based home exercise programming in adults with persisting oculomotor deficits post-concussion.
Biological sex and sociocultural gender differences in concussion reporting, symptom experience, and recovery have been documented, yet sex and gender have not been adequately explored in the context of OMR. This trial is designed to collect sex-disaggregated data to inform future research in this area.
Objectives The primary objective is to assess the feasibility of a future fully powered RCT, operationalized across four a priori criteria: recruitment, retention, adherence, and technology reliability.
The secondary objective is proof-of-concept, operationalized a priori as participant-rated perceived benefit (0-4 scale) at study completion.
Study Design This is a feasibility RCT with two parallel intervention groups, a 1:1 allocation ratio, conducted at Toronto Rehabilitation Institute (TRI)-University Health Network (UHN), Ontario, Canada.
Recruitment Participants are recruited through hospital- and community-based concussion clinics, community-based brain injury organizations, and social media platforms. Individuals who participated in prior research at the Hull-Ellis Concussion and Research Clinic, had not recovered, and had indicated willingness to be contacted for future eligible studies are also approached. Interested individuals undergo telephone-based screening followed by in-person confirmation of visually based eligibility criteria. Written informed consent is obtained prior to enrolment.
Eligibility
Exclusion criteria
Baseline Measures Baseline data include demographics, medical history, injury characteristics, and the following validated questionnaires: Brain Injury Visual Symptom Survey (BIVSS), Convergence Insufficiency Symptoms Survey (CISS), RPQ, Patient Health Questionnaire-9 (PHQ-9), Fatigue Severity Scale (FSS), Insomnia Severity Index (ISI), Sheehan Disability Scale (SDS), Traditional Masculinity and Femininity Scales (TMS/TFS), and the Visually Induced Motion Sickness Susceptibility Questionnaire (VIMSSQ). Clinical assessments include near point of convergence break (NPC, in centimeters) and critical flicker fusion (CFF, in hertz).
Interventions Oculomotor Rehabilitation (OMR) Group: Participants receive six weekly in-person sessions of progressive, personalized OMR delivered via head-mounted VR goggles (FOVE) using NeuroFlex software, targeting saccades, smooth pursuits, vergence, gaze stability, optokinetic reflex, and anti-saccades. Sessions increase progressively in difficulty and duration based on individual tolerance. Between sessions, participants complete daily home-based eye movement exercises via a study-specific mobile application, targeting at least 10 minutes per day, five days per week.
Usual Care (UC) Group: Participants receive education on visual symptom-limiting strategies (e.g., pacing, screen modification). No active or sham intervention is provided.
Randomization and Allocation Participants are randomized 1:1 to OMR or UC following consent, using a blinded, sex-stratified randomization schema with variable block sizes generated a priori. Blinding of participants and study personnel after allocation is not possible given the nature of the intervention.
Outcome Measures Primary Feasibility Outcomes are assessed against a priori traffic light criteria (Green/Amber/Red) and include: recruitment rate, randomization rate, compliance to allocated arm, and retention rate.
Additional Feasibility Outcomes include: magnitude of co-intervention, VR tolerability, homework participation, study experience rating (0-4), technology reliability, and the ability of the technology to capture change in oculomotor metrics between baseline and final assessment.
Secondary Outcome: Participant-rated perceived benefit (0-4) at study completion.
Data Analysis Descriptive statistics are used to summarize feasibility outcomes and participant characteristics. The study is not powered for efficacy testing and between-group comparisons are not emphasized. Variability estimates will inform power calculations for a future full-scale RCT. Data are captured in REDCap and analyzed in SPSS (Version 25). A missing data threshold of 5% is set a priori, with complete case analysis below this threshold and multiple imputation applied above it.
Findings from this feasibility trial will be used to inform the design of a future fully powered pragmatic RCT. Feasibility metrics including recruitment and retention rates, compliance to allocated arm, and technology reliability, will be evaluated against a priori traffic light criteria to determine whether, and under what conditions, progression to a full trial is warranted. Variability estimates across candidate clinical outcomes and review of recent published literature will additionally inform outcome selection and power analysis planning for the future trial.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The UC group is education only and consists of education on visual symptom-limiting strategies and resources. These include strategies such as pacing and taking breaks during visual work, strategies to modify a visual stimulus such as increasing font size on a mobile application or changing to dark mode. An active or 'sham' is not provided.
Participants engage in eye movement training based on the following movements:
Between study visits, participants compete home based exercises on a smart phone or tablet.
Time frame: 12 months
Defined as the ability to recruit at least 32 individuals over a 12 month period.
Time frame: Measured at final testing (8 weeks post enrollement).
Perceived benefit of OMR in contributing to improvement in symptoms of concussion of at least 85% as measured on a scale of 0-4 (0 no benefit to 4 significant benefit) as reported after participating in 6 weekly sessions of OMR. Measured at final testing for participants in the OMR group.
Time frame: At study completion (approximately 8 weeks per participant).
The percentage of participants completing all study requirements including: Baseline data collection, the assigned intervention, and final testing. The assigned intervention as described in the intervention section.
Time frame: From enrolment to final testing at 8 weeks post enrolment.
No harms or adverse events (undesirable or unintended medical occurrence experienced by a study participant, regardless of whether it is directly caused by the intervention) reported by any participant from baseline through final testing, including during and immediately after intervention.
Time frame: Over the 12-month recruitment period.
The proportion of eligible participants who enrolled and were randomized out of the total number of individuals interested in the study.
Time frame: Over 6 week intervention period, measured at final testing 8 weeks post enrollment.
The proportion of participants who adhered to their assigned arm allocation (no withdrawals or crossovers) through study completion.
Time frame: Throughout the 6-week intervention period.
Frequency and nature of non-study rehabilitation or therapeutic interventions participants engaged in during the study period, as self-reported.
Time frame: Immediately after each weekly OMR intervention session; (for 6 weeks).
Measured using the Simulator Sickness Questionnaire (SSQ; Kennedy et al., 1993), a 16-item scale (0=not at all, 3=severe) oculomotor and nausea related symptoms.
Time frame: Measured weekly over the 6-week intervention period.
Number of days participants reported completing at-home eye movement exercises (out of 5 days per week, excluding weekends).
Time frame: Measured once after final testing (8 weeks post enrollment).
Overall perceived experience with the study rated on a 0-4 scale (0=negative, 2=neutral, 4=positive)
Time frame: At each participant visit over the entire study period (approximately 16 months).
Frequency of technology failures during VR delivery requiring rescheduling or session interruption.
Time frame: From baseline to final testing 8 weeks post enrollment.
The ability of the VR platform to capture clinically meaningful change in oculomotor parameters (saccade latency, smooth pursuit gain, vergence amplitude) between baseline and final testing.
Time frame: Baseline and final testing (8 weeks post-randomization)
Participant completion rates and variance estimates of the Brain Injury Visual Symptom Survey (BIVSS, score range 0-112; higher=worse symptomology) to inform power calculations for a future trial.
University Health Network, Toronto
Other
Acronym: ORCA
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02710123
Brain Concussion, Brain Diseases
Buffalo, New York, United States
View Trial DetailsNCT05629169
Brain Concussion, Brain Diseases
New York, United States
View Trial DetailsNCT01398566
Brain Concussion, Brain Diseases
Columbus, Ohio, United States
View Trial DetailsNCT02714192
Brain Concussion, Brain Diseases
Buffalo, New York, United States
View Trial Details